MiNK Therapeutics (INKT) Fundamentals 2026 — Revenue Analysis | SniperIQ

0.89 on the NASDAQ. This SniperIQ fundamentals page covers MiNK Therapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is MiNK Therapeutics's market cap?

MiNK Therapeutics (INKT) has a market capitalization of approximately $54M, trading at

0.89 on the NASDAQ. Market cap moves with the live share price.

How profitable is MiNK Therapeutics?

MiNK Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does MiNK Therapeutics pay a dividend?

MiNK Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is MiNK Therapeutics financially healthy?

MiNK Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 1.38x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is MiNK Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MiNK Therapeutics (INKT) the key facts are: market cap $54M, 52-week range 8.48-21.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.